Colony stimulating activity in the serum of patients with multiple myeloma is enhanced by interleukin 3: a possible role for interleukin 3 after high dose melphalan and autologous bone marrow transplantation for multiple myeloma.
Sera from 36/37 multiple myeloma patients and 19/21 sera from patients with other solid or liquid tumours had granulocyte-macrophage colony stimulating activity (CSA) towards normal human donor bone marrow whereas 1/16 sera from normal donors had this activity. Unlike human rhGM-CSF and GM-CSF from 5637 (human bladder cell line) conditioned medium which is heat stable, CSA from serum is heat labile (56 degrees C/30 min). In multiple myeloma patients, CSA was detectable more than 2 years after treatment with 'high dose melphalan. Although multiple myeloma patients, at relapse, have sufficient CSA in their serum to produce maximal stimulation of GM-CFUc from normal donor bone marrow in vitro, their own GM population responds poorly. The results suggest that the failure of patients own bone marrow to respond to endogenous CSA may be due to damage to the stem cells of the marrow or the failure of precursor cells to respond to CSA. Addition of rhIL-3 to myelomatous serum increased the number of GM-CFUc from both normal and myelomatous bone marrow but did not stimulate the growth of MY-CFUc significantly. The results suggest that rhIL-3 may assist bone marrow recovery in multiple myeloma patients after intensive chemotherapy.
Section of Medicine, Institute of Cancer Research, Sutton, Surrey, U.K.
B C
BC
Millar
J B
JB
Bell
A
A
Montes
J L
JL
Millar
J A
JA
Maitland
J
J
Treleaven
C
C
Viner
M
M
Gore
T J
TJ
McElwain
D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation; D003114:Colony-Forming Units Assay; D003115:Colony-Stimulating Factors / Q000494:pharmacology; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000097:blood* / Q000494:pharmacology; D006801:Humans; D007377:Interleukin-3 / Q000494:pharmacology*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000097:blood* / Q000473:pathology / Q000628:therapy; D009930:Organic Chemicals; D011994:Recombinant Proteins / Q000494:pharmacology; D014410:Tumor Stem Cell Assay
D003115:Colony-Stimulating Factors; D006133:Growth Substances; D007377:Interleukin-3; D009930:Organic Chemicals; D011994:Recombinant Proteins; C042320:colony promoting activity; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D008558:Melphalan